The Series B financing was led by Parkwalk Advisors and BGF to support the commercial scale-up of power transistors.
"CGD is poised to become one of the leaders in enabling a sustainable world. As we move to a net-zero carbon society with rapidly increasing levels of electrification, we need clean, renewable sources of electricity and more efficient conversion methods. GaN provides the optimum conversion solution, reducing power losses by more than 50% and increasing energy conversion efficiency to above 99%. To take just one application example, if all data centres were to adopt GaN, this would save 12.4TWh of electricity per year, or 9 million tons of CO2 – the equivalent of taking 1.9 million internal combustion engines vehicles off the road for a year *. Our ICeGaN™ GaN transistors – which are now in the hands of customers at scale – are amongst the most efficient devices of their type on the market. Our devices are also the easiest for designers to use."
The financing round was led by BGF and Parkwalk Advisors to support platform expansion and team growth.
"These are incredibly exciting times for the genomics community and we are proud to pioneer the advent of a new era for patient-centric medicine. We are delighted to have the support of BGF, Parkwalk and our existing investors Bioqube and Jonathan Milner, which provides validation of our technology platform, GenLink3DTM."
The funding round was led by Foresight Group alongside existing investors Parkwalk Advisors and Oxford Science Enterprise.
"Opsydia’s technology has the potential to become the de facto marking standard in the diamond industry for the next 20 years. We look forward to supporting Opsydia’s experienced Management team as they deliver on this ambition."
The financing round was co-led by Lansdowne Partners, Oxford Science Enterprises, and Parkwalk Advisors.
"Global agriculture needs a new Green Revolution if we are to feed the world sustainably. Being able to control weeds is critical to both yield and the cost of production in most crops and new herbicide modes of action are essential. It’s very exciting to see moa starting to play its part in this new revolution by advancing so far in such little time."
The digital healthcare start-up secured backing from IP Group and Parkwalk Advisors to scale operations in Europe and the US.
"However, due to resource costs and poor logistics, current health systems cannot deliver the amount of therapy needed, with significant backlogs, and few patients receiving anywhere near what they require to get better. This is a common problem faced by hundreds of millions of patients around the world, with inefficient care pathways not only costing health systems hundreds of billions of dollars every year, but costing people a chance to live their lives to their full potential."
